What Makes RESI Europe Stand Out

25 Apr

By Rikki Piccirillo, Marketing Manager, LSN

Rikki

We are excited to introduce RESI Barcelona 2024, where innovation converges with investment in Europe’s thriving life sciences ecosystem. Join us as we explore the dynamic opportunities highlighted by Greg Mannix, VP International Business Development at Life Science Nation.

RESI Barcelona 2024 combines in-person networking with a hybrid digital format, offering unparalleled access to over 300 early-stage companies. From the Innovators Pitch Challenge to engaging panels and workshops, RESI Barcelona promises a platform for startups to showcase cutting-edge technologies and connect with investors seeking the next big breakthrough.

English

Español

Register-now-button-new

RESI-Europe-2024-Banner-1100pxw

Exhibit at RESI Europe 

25 Apr

By Cameron Hurlburt, Director of Business Development, LSN

RESI returns to Europe at the Hilton Diagonal Mar Hotel in Barcelona. This conference is a hybrid format; in person on Monday, June 17 followed by two days of virtual partnering. Past in-person RESIs boasted a vibrant network of service providers, including CRO/CMOs, non-profits, suppliers, and professional services like law firms and banks. These service providers have played an essential role in the RESI ecosystem, and we are pleased to welcome them back with more offerings that include onsite and digital formats to promote their services and connect them with early-stage startups who need them.

DSC1819McDermott Will & Emery a global law firm exhibited at RESI South on March 25, 2024.

RESI’s unique value to its service providers is its dedication to early-stage companies in life science and healthcare. These startups have specific needs that make them ideal clients for a variety of providers. CRO/CMOs attend RESI to connect with preclinical therapeutics. Lab services with valuable R&D space, banks with life science-specific benefits, and law firms specializing in IP, term sheet negotiations, and more exhibit at RESI to connect with these founders who seek their services.

DSC9738-scaledCambridge Innovation Center exhibited at RESI Boston on June 5, 2023.

RESI exhibition includes a table for promotion and networking in the exhibit hall. Exhibitors also have their logo featured prominently on the RESI website, program guide, and onsite signage. The exhibitor package also includes a complimentary registration to participate in the partnering platform and attend all conference events. Interested in reaching a broad audience of early-stage entrepreneurs at RESI Europe Barcelona? Contact us to learn more!

RESI-Europe-2024-Banner-1100pxw

IPC Winner, Sanguina, Finds Connection at RESI South 

25 Apr

Interview with Erika Tyburski, CEO at Sanguina and Maria Thacker-Goethe, President & CEO at Georgia Bio By Caitlin Dolegowski, Marketing Manager, LSN

Erika TyburskiErika Tyburski
Maria Thacker-GoetheMaria Thacker-Goethe
CaitiCaitlin Dolegowski

Caitlin Dolegowski (CD): Please introduce us to Sanguina and the company’s technology (and curious about the naming of your company).

Erika Tyburski (ET): Hi Caitlin. Sanguina means blood in Latin and is also derived from the English word sanguine- or relaxed. I co-founded Sanguina to make accessible tools to learn more about your health. We have a focus on blood health, and making tools that tell you something about blood. We are passionate about blood because it often changes first in response to a stress on the system- a cold, a deficiency, or a chronic disease. This is why blood testing is often used for diagnoses. Our first platform is called AnemoCheck for accessible and rapid anemia management. We recently received FDA-clearance on a home test for hemoglobin level determination and have a complementary smartphone application for determining likelihood of anemia based on the paleness of fingernails via a fingernail selfie.

CD: Maria, please introduce us to Georgia Bio. RESI South took place in Atlanta and there were many companies from Georgia represented RESI. Tell us about the life sciences ecosystem in Georgia and exciting companies emerging, such as Sanguina.

Maria Thacker-Goethe (MT): Georgia Bio is the life science association focused on enhancing the innovation environment in Georgia. Our main goals are advocating for favorable policies, linking members with funding and partners, and supporting workforce development in the state.

Sanguina is one of our standout companies, but it’s not alone. At the RESI conference, we also had Andson Biotech, Aruna Bio, and Emtherapro presenting to the 350 attendees. These companies represent our growing ecosystem. The life sciences sector in Georgia has seen significant growth, with a 20% increase in jobs since 2015, totaling 11,225, and generating a total economic impact of $50.2 billion, according to Biopharma Reporter. Georgia is emerging as a prominent life science hub.

CD: Maria, I know you have been to RESI before, Erika, this was your first conference. What are your experiences at RESI? What worked well for you both at RESI South?

ET: The event was very efficient. The networking platform enabled meetings to be made ahead of the event and the rapid 20-minute meetings allowed me to meet with many parties in a short amount of time. Talk about bang for buck! I found myself re-connecting with people that have seen me grow locally and meeting new people in the southeast region. I particularly enjoyed the pitch session and constructive questions given to me by the digital health panel.

MT: First off, I had a great experience at the RESI South event last month. My team and I had more than a dozen meetings with life science companies in the state. Although Georgia has all the seeds needed to grow a robust ecosystem, one of the big gaps is venture funding. That is why the state associations partnered with Life Science Nation. We are excited about our partnership and look forward to even stronger future events.

CD: Erika, what stage of fundraising is Sanguina in and what are your goals in 2024?

ET: We have closed our first priced round. Sanguina is fortunate enough to have completed our raise and we are looking to go to work and generate recurring revenue this year and next. Sanguina is primarily a B2B company, so I am aiming to onboard several new customers and execute contracts for custom versions of our products. I look forward to profitability, with my next round focused on growth.

CD: Congratulations on your second-place finish at RESI JPM’s Innovator’s Pitch Challenge (IPC)! What do you think was the key to your success and standing out at RESI JPM?

ET: I’ve pitched a lot. I’ve been given thousands of questions on Why? How? When? And I’ve learned in that time to be as honest as possible. I’m not afraid to say: “I’m working on that answer”, while also acknowledging that “I’ve faced many challenges, and know how to overcome” I think investors and experts in my industry appreciate my candor. Additionally, I learn by doing, so throughout the years, I haven’t been afraid to Just Do It. I’ve learned how to run clinical studies, how to execute a regulatory strategy, how to raise money, how to close that first customer.

CD: What advice would you like to give to fellow entrepreneurs about RESI conferences?

ET: Have confidence in what you do and know. Be humble and talk to everyone, you never know what one new connection will lead to. And use the networking platform, of course!

MT: My biggest piece of advice is to use the partnering system to meet investors. Over 200 investors attended RESI South, either in person or virtually, which the Southeast has never seen. These investors want to meet with you to get to know you and your business.


If you’re interested in the next upcoming Innovator’s Pitch Challenge, you can apply for the RESI Europe 2024 IPC taking place June 17-19 with a 1-day in-person conference follow by 2-day virtual partnering at Hilton Diagonal Mar Barcelona in Barcelona, Catalonia, Spain. Applications are accepted on a rolling basis, so get your application submitted today!

RESI-Europe-2024-Banner-1100pxw

Register-now-button-new

Hot Investor Mandate: USA-Based Firm Invests in Therapeutics, Medical Devices, and Diagnostics Companies in US, Europe, Israel With Inaugural Life Sciences Fund

25 Apr

A merchant bank operates investment and advisory platforms while also being an active investor on a principal basis. The firm invests in a variety of industries including media & entertainment, renewable energy, digital assets, consumer, and life sciences. The firm recently had an initial close on their inaugural life sciences fund, and is actively seeking early-stage investment opportunities in Series A to C rounds. Initial check sizes will be between $3-7M with reserved follow-on investments. The firm focuses US-based companies, and will consider those based in Europe, Israel, and other geographies who are looking to expand operations or relocate to the US. 
 
Within life sciences, the firm will consider opportunities in therapeutics, medical devices, and diagnostics. The firm does not invest in digital health or healthcare IT-based solutions. The firm is opportunistic and will consider all types of novel modalities, technologies, and disease areas that address a high unmet medical need. While the firm does invest in early-stage companies, the firm will expect companies to have a lead asset and indication in place, demonstrating strong pre-clinical data and be close to IND filing. 
 
The firm seeks to work with companies with a committed, full-time management team in place. The firm typically does not lead investment rounds and prefers to syndicate with other likeminded investors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Hot Investor Mandate: Corporate Venture Fund Seeks Biotech Investment Opportunities in the US, China, and Europe, from Seed Stage to IPO

25 Apr

As a corporate venture arm of a leading global service provider, the fund is open to investing in anywhere from seed to IPO financing rounds. Initial investment size can vary and follow-on investment is possible. The firm primarily seeks opportunities in the US, and is open to China and Europe as well. The firm does not lead rounds and prefers companies with a lead investor in place.  Depending on the investment size and deal terms, the fund may consider an observer seat or board seat. The firm makes equity investments only and does not have an equity-for-service model.  

Separately from the corporate venture arm, the parent company also runs a program for which it collaborates with over 25 partners, such as accelerators, seed/venture capital firms, incubators, and other similar programs to provide startups various tools and resources to accelerate biologics and vaccine development, including credits for the firm’s technology platforms. Startups must be an active participant or referred by a Program Partner to be eligible. 
 
The firm will consider a wide range of biotech assets, from antibody drug, protein therapeutics, vaccines, DNA and mRNA drugs. The fund is also open to orphan drugs. One type of asset that the fund does not consider cell and gene therapy. 
 
The firm does not lead rounds therefore would only invest when a lead investor is secured. The fund is open to working with new or first time founders but hopes to see that the team has a good supportive network. The fund is interested in working with founders who are open to advice and suggestions. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Hot Investor Mandate: VC Firm Invests in Seed to Series B Life Science Technologies Addressing Underserved Populations and Geographies in the US

25 Apr

A venture capital firm based in Seattle, Washington is looking to make another 10 investments with its current fund. The fund primarily invests in Series A, but is open to Seed and Series B. The typical check size is between $250K – $2M, dependent on the stage of investment. The firm identifies themselves as very involved investors and will not invest until they see a clear path through which they can add value to the company. The firm has a strong diversity lens and looks for diverse teams including women and individuals of different backgrounds. The firm invests in USA based companies. 

 
The firm will invest in therapeutics, diagnostics, medical devices, and digital health. The fund is particularly interested in companies targeting health related issues impacting underserved populations and geographies, such as diabetes, cancer, femtech, and cardiovascular health. The fund looks for therapeutics companies to be within 6 months of submission for phase 1 trials. The fund will look at medical device companies within 6 months of 510(k) approval. The fund also requires that there is an MVP and customer attraction but does not require there to be revenue. Similarly with diagnostics, the firm requires an MVP but does not require revenue. The fund does require digital health companies to have revenue. 
 
The firm prefers to work with management teams with prior experience with startups or within the industry, but is not a firm requirement. The firm will lead or co-invest. The firm requires a board seat when leading rounds. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Hot Investor Mandate: Europe-Based VC Looks to Invest in Pre-Seed to Series A Rounds for Pre-Clinical Stage Drug Development Companies

25 Apr

A firm based in Europe raised a second fund with €60M under management for Pre-Seed, Seed, and Series A investments. The fund is backed by a majority of private investors with the support of a number of institutional investors such as European Investment Fund (EIF). The firm invests €1-2M as a seed investment in the form of equity or convertible notes to help companies advance into preclinical proof of concept and can continue investing up to €6M. If additional funds are needed, the firm seeks co-investments from the strong network of investors they have in Europe. The firm is looking for investments across Europe. 
 
The firm invests in the biotech sector, exclusively in the drug development space, and with a preference for Advanced Therapies and Synthetic Biology. The firm has an interest in cutting edge technology, and it specializes in tech transfer opportunities. The firm is agnostic indication-wise and will invest in projects in preclinical stage that have reached an in vivo proof of concept in an animal model relevant for the disease for which the therapy is being developed. 
 
The firm looks for companies with a scientific founder, and preferably a C-Level executive with a track record in biotech or pharmaceutical companies. The firm prefers to lead or co-lead in Seed stage therapeutics companies and will seek a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.